PhRMA nudges BIO on marketing code
Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America, is continuing to publicly pressure Jim Greenwood, president of Biotechnology Industry Organization, to adopt PhRMA's marketing code. BIO has been considering it, but says the code may be a difficult fit because few of its members market products and the products promoted are complex (1"The Pink Sheet" DAILY, Nov. 18, 2008). At a briefing for reporters Jan. 14, Tauzin said, "Jim tells me ... [that] sometime in February or March they are planning to make a decision, and hopefully they'll endorse the code." For its part, BIO said, "We have no specific timetable set for this discussion.
You may also be interested in...
Limits on physician interactions might not be appropriate when trying to educate doctors on complex, large-molecule products, the biotech group believes.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.